Medical/Pharmaceuticals
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, b...
2024-01-08 22:00
5074
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced thatMichelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company's achievements in the development of new bispecific a...
2024-01-08 21:38
1406
YS Biopharma Announces Changes to its Board Committees
GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-01-08 21:00
1490
Novel Technology Transforms Baldness Treatment Using Beard and Body Hair
LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss. A breakthrough emerges with Dr. U Hair and Skin Clinic reports a pioneering study published in the esteemed Dermatologic Surgery journal tit...
2024-01-08 21:00
1589
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
* Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in m...
2024-01-08 20:30
1512
The World's First Clinical Base Editing Therapy for Hemoglobinopathy
CorrectSequence Therapeutics' CS-101 Successfully Cures One Patient of
Transfusion-Dependent β-Thalassemia
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 8, 2024, Shanghai,China,
CorrectSequence Therapeutics Co., Ltd.
2024-01-08 19:46
1920
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024 NEWARK, Del. and NANJING, China, Jan. 8, 2024 /PRNewswire/ -- The Partner ...
2024-01-08 19:35
1175
So-Young Announces Update on Repurchase and Cancellation of Shares
BEIJING, Jan. 8, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that during the term of the Co...
2024-01-08 19:00
4576
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
* The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S. * The site is expected to employ 250 people when fully operational. WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resea...
2024-01-08 17:52
4396
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report
Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organ...
2024-01-08 16:00
1488
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biops...
2024-01-08 15:30
1521
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease
NEW TAIPEI CITY, Jan. 8, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the United States Food and Drug Administration (U.S. FDA) has accepted the CBL-514 Investigational New Drug (IND) application of CBL-0202 DD Phase 2 Study to treat Dercum's Disease. Dercum's disease...
2024-01-08 13:25
2134
2024 Trend Forecast for Cosmetic Surgery & Medical Aesthetics in Singapore
As the demand for medical aesthetics and cosmetic surgery continues to grow, Dr Ivan Puah, a liposuction and aesthetic doctor from Amaris B. Clinic, identifies a distinct shift in consumer needs inSingapore. SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Dr Ivan Puah, Medical Director of Amaris B. Cli...
2024-01-08 09:00
415
Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023
SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Juniper Biologics
2024-01-08 09:00
1779
Suvoda Announces 30% Growth in 2023 Driven by Strong Customer Adoption of New Suvoda Platform and Products
Company maintained industry-leading quality metrics throughout growth surge. PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, su...
2024-01-08 08:00
1553
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis
- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. - Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worl...
2024-01-08 07:00
1442
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab(开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XEL...
2024-01-05 21:00
5693
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement onEribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countr...
2024-01-05 19:44
2982
Grant of Restricted Share Units to Mr. Xing Jin
BEIJING, Jan. 5, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that the Compensation Committe...
2024-01-05 19:00
6126
SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease
* Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights forGreater China and Singapore * Transaction reflects the Novartis commitment to the Chinese market and complements existing pipeline in renal diseases. SHANGHAI, Jan. 5, 2024 /PRNewswire/ -- San...
2024-01-05 16:00
2493
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8873
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7709